← Back to headlines
RBC Capital Lowers Price Target for Viridian Therapeutics to $42
RBC Capital has lowered its price target for Viridian Therapeutics, Inc. (VRDN) to $42, while still maintaining an Outperform rating on the stock.
6 Mar, 15:20 — 6 Mar, 15:20
Sources
Showing 1 of 1 sources
